

SPINE SAFETY WARNING:

**Information for Healthcare Professionals:
Mobic (meloxicam) Tablets and Oral Suspension:
Labeling Changes**

According to MedWatch, FDA notified healthcare professionals of labeling changes for Mobic (meloxicam) Tablets and Oral Suspension. The following has been added to the labeling:

WARNINGS AND PRECAUTIONS

Co-administration with Kayexalate (sodium polystyrene sulfonate)

- Concomitant use of sorbitol with Kayexalate (sodium polystyrene sulfonate) has been implicated in cases of intestinal necrosis (possibly fatal). Due to the presence of sorbitol in Mobic Oral Suspension, use with Kayexalate is not recommended.

DRUG INTERACTIONS

Kayexalate (sodium polystyrene sulfonate)

- Cases of intestinal necrosis (possibly fatal) have been described in patients who received concomitant sorbitol and Kayexalate (sodium polystyrene sulfonate). Due to the presence of sorbitol in Mobic Oral Suspension, use with Kayexalate is not recommended.

The North American Spine Society is committed to quality patient care through promotion of patient safety and prevention of medical errors. NASS monitors a variety of government and other resources for patient safety related notices that may be useful to our members. Information from these notices is also archived on the NASS website at <http://www.spine.org/Pages/PracticePolicy/ClinicalCare/SpineSafetyAlerts/Default.aspx>. This information is provided as a service for information and education only.